European Bioinformatics Institute

Report: Vast swathes of human biology untouched by drug discovery programs

Monday, December 5, 2016

Scientists have created a map of all 1,578 licensed drugs and their mechanisms of action—as a means of identifying ‘uncharted waters’ in the search for future treatments. Their analysis of drugs licensed through the FDA reveals that 667 separate proteins in the human body have had drugs developed against them—just an estimated 3.5% of the 20,000 human proteins.

[Read More]

Biogen joins Center for Therapeutic Target Validation

Wednesday, February 10, 2016

Biogen has joined the Center for Therapeutic Target Validation (CTTV), a public-private collaboration to improve the success rate for discovering new medicines. Originally formed by GlaxoSmithKline, the Wellcome Trust Sanger Institute and the European Bioinformatics Institute (EMBL-EBI), the CTTV fosters deep, ongoing interactions between academic and industry members for the purpose of developing open, transformative approaches to selecting and validating novel targets in drug development.

[Read More]

GSK, EMBL-EBI, Wellcome Trust form ‘big data’ research initiative

Friday, March 28, 2014

A pioneering public-private research initiative between GlaxoSmithKline, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute has formed to harness the power of “big data” and genome sequencing to improve the success rate for discovering new medicines. The new Center for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery.

[Read More]